Haemodynamic effects of different anti-hypertensive drugs.

• Other Authors: Lau, Siu Wai Maggie.
• Format: Others
• Language: English
• Published: Chinese University of Hong Kong 1995
• Subjects: Antihypertensive agents > Pharmacology; Hypertension > Drug therapy
• Online Access: http://library.cuhk.edu.hk/record=b5888527; http://repository.lib.cuhk.edu.hk/en/item/cuhk-320698

Lau Siu Wai Maggie. === Thesis (M.Phil.)--Chinese University of Hong Kong, 1995. === Includes bibliographical references (leaves 236-245). === List of Figures --- p.i === List of Tables --- p.viii === List of Abbreviations --- p.x === Abstract --- p.xii === Chapter Chapter 1 --- Introduction --- p.1 === Chapter 1.1 --- Postulated Pathophysiology of Essential Hypertension --- p.1 === Chapter 1.2 --- Measurement of Cardiac Output (CO) by Transthoracic Electrical Bioimpedance (TEB) and Other Methodologies --- p.6 === Chapter 1.3 --- Measurement of Blood Pressure --- p.10 === Chapter 1.4 --- Use of Antihypertensive Agents in Essential Hypertension --- p.12 === Chapter Chapter 2. --- The Method of Transthoracic Electrical Bioimpedance --- p.15 === Chapter 2.1 --- Introduction --- p.15 === Chapter 2.2 --- Development of Theory --- p.18 === Chapter 2.3 --- Measurements of Haemodynamic Parameters --- p.24 === Chapter 2.4 --- Literature Review - Validity of the Technique --- p.30 === Chapter Chapter 3 --- A Study on Reproducibility of Thoracic Electrical Bioimpedance in Healthy Subjects --- p.39 === Chapter 3.1 --- Objectives --- p.39 === Chapter 3.2 --- Methodology --- p.39 === Chapter 3.2.1 --- Subjects --- p.39 === Chapter 3.2.2 --- Study design --- p.41 === Chapter 3.2.3 --- Non-invasive haemodynamic monitoring --- p.41 === Chapter 3.2.4 --- Blood Pressure Measurement --- p.43 === Chapter 3.2.5 --- Isometric Exercise --- p.43 === Chapter 3.2.6 --- Data analysis --- p.44 === Chapter 3.2.7 --- Statistical analysis --- p.46 === Chapter 3.3 --- Results --- p.50 === Chapter 3.3.1 --- Systolic blood pressure --- p.50 === Chapter 3.3.2 --- Diastolic blood pressure --- p.52 === Chapter 3.3.3 --- Mean arterial pressure --- p.54 === Chapter 3.3.4 --- Heart rate --- p.55 === Chapter 3.3.5 --- Thoracic fluid index --- p.58 === Chapter 3.3.6 --- Stroke index --- p.60 === Chapter 3.3.7 --- Cardiac index --- p.62 === Chapter 3.3.8 --- Systemic vascular resistance index --- p.65 === Chapter 3.4 --- Discussion --- p.70 === Chapter Chapter 4 --- Literature Review --- p.73 === Chapter 4.1 --- Atenolol: Beta-adrenoceptor antagonists with β1-selectivity --- p.73 === Chapter 4.2 --- Pindolol: Beta-adrenoceptor antagonists with ISA --- p.78 === Chapter 4.3 --- Alpha1-adrenoceptor antagonists --- p.81 === Chapter 4.4 --- Angiotensin Converting Enzyme Inhibitors --- p.84 === Chapter 4.5 --- Calcium Channel Blockers --- p.87 === Chapter 4.6 --- Central Alpha Agonist --- p.91 === Chapter 4.7 --- Thiazide Diuretics --- p.94 === Chapter Chapter 5 --- The Integrated Hypertension Study --- p.97 === Chapter 5.1 --- Objectives --- p.97 === Chapter 5.2 --- Methodology --- p.97 === Chapter 5.2.1 --- Subjects --- p.97 === Chapter 5.2.2 --- Study design --- p.109 === Chapter 5.2.3 --- Non-invasive haemodynamic monitoring --- p.110 === Chapter 5.2 4 --- Blood Pressure Measurement --- p.111 === Chapter 5.2.5 --- Isometric Exercise --- p.111 === Chapter 5.2.6 --- Data analysis --- p.111 === Chapter 5.2.7 --- Statistical analysis --- p.112 === Chapter 5.2.8 --- Limitations of the study --- p.113 === Chapter 5.3 --- Results --- p.117 === Chapter 5.3.1 --- Atenolol --- p.117 === Chapter 5.3.2 --- Pindolol --- p.125 === Chapter 5.3.3 --- Doxazosin --- p.132 === Chapter 5.3.4 --- Enalapril --- p.138 === Chapter 5.3.5 --- Nifedipine Retard --- p.145 === Chapter 5.3.6 --- Methyldopa --- p.152 === Chapter 5.3.7 --- Cyclopenthiazide --- p.160 === Chapter 5.4 --- Comparisons of the anti-hypertensive drugs studied --- p.167 === Chapter 5.4.1 --- Baseline values --- p.167 === Chapter 5.4.2 --- Percentage changes after active treatment --- p.170 === Chapter 5.5 --- Discussion --- p.196 === Chapter 5.5.1 --- Atenolol --- p.196 === Chapter 5.5.2 --- Pindolol --- p.199 === Chapter 5.5.3 --- Doxazosin --- p.200 === Chapter 5.5.4 --- Enalapril --- p.202 === Chapter 5.5.5 --- Nifedipine Retard --- p.203 === Chapter 5.5.6 --- Methyldopa --- p.204 === Chapter 5.5.7 --- Cyclopenthiazide --- p.205 === Chapter 5.5.8 --- Comparison of the anti-hypertensive drugs studied --- p.206 === Chapter Chapter 6 --- Acute haemodynamic effects of Atenolol and Pindolol --- p.208 === Chapter 6.1 --- Objectives --- p.208 === Chapter 6.2 --- Methodology --- p.208 === Chapter 6.2.1 --- Subjects --- p.208 === Chapter 6.2.2 --- Study Design --- p.209 === Chapter 6.2.3 --- Statistical analysis --- p.209 === Chapter 6.3 --- Results --- p.211 === Chapter 6.3.1 --- Acute haemodynamic changes of atenolol --- p.211 === Chapter 6.3.2 --- Acute and short-term haemodynamic changes of atenolol --- p.219 === Chapter 6.3.3 --- Acute haemodymmic changes of pindolol --- p.221 === Chapter 6.3.4 --- Acute and short-term haemodymmic changes of pindolol --- p.222 === Chapter 6.3.5 --- Comparison of the acute haemodymmic effects of atenolol and pindolol --- p.226 === Chapter 6.4 --- Discussion --- p.230 === Chapter Chapter 7 --- Conclusion --- p.232 === References --- p.236 === Acknowledgements